ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period

LONDON — (BUSINESS WIRE) — For media and investors only ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (「GSK」), with Pfizer Inc. and Shionogi L…